Company
Intellia Therapeutics
Intellia Therapeutics has 6 drugs tracked on RxWires: 3 in Phase 3, 3 in Phase 1/2.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| NTLA-2002 | Phase 3 | Hereditary Angioedema |
| nexiguran ziclumeran | Phase 3 | Neuromuscular Disease |
| NTLA-2001 | Phase 3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy |
| Arm 1: NTLA-5001 | Phase 1/2 | Acute Myeloid Leukemia |
| Biological NTLA-2002 | Phase 1/2 | Hereditary Angioedema |
| Biological NTLA-3001 | Phase 1/2 | Lung Disease |
Latest
- intellia therapeutics filed 8-K
- Priority Review: intellia therapeutics
- intellia therapeutics filed 8-K
- intellia therapeutics filed 8-K
- intellia therapeutics filed 8-K
Follow Intellia Therapeutics on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.